• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2012 Product Image

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2012

  • ID: 2335415
  • November 2012
  • 80 pages
  • Global Markets Direct

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) 9
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics under Development by Companies 11
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics – Products under Development by Companies 18
Companies Involved in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Development 19
Sequella, Inc. 19
Merck & Co., Inc. 20
Actelion Ltd 21
Cubist Pharmaceuticals, Inc. 22
ViroPharma Incorporated 23
Optimer Pharmaceuticals, Inc. 24
Paratek Pharmaceuticals, Inc. 25
Intercell AG 26
Oragenics, Inc. 27
e-Therapeutics plc 28
ActogeniX NV 29
ImmunoBiology Limited 30
Aquapharm Biodiscovery Limited 31
Microbiotix, Inc. 32
Sorrento Therapeutics, Inc. 33
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
surotomycin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
fidaxomicin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SQ-109 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ACAM-Cdiff - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
oritavancin disphosphate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SQ-641 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ETX1153c - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MK-3415A - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VP-20621 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
tetracycline - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
cadazolid - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
IC-84 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ActoBiotics For Clostridium Difficile Enteropathy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AQP-182 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MBX-500 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MU1140-S - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics – Drug Profile Updates 62
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics – Discontinued Products 72
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Product Development Milestones 73
Featured News & Press Releases 73
Nov 01, 2012: Optimer Initiates Phase IIIb Clinical Trial Of Dificid For Prevention Of Clostridium Difficile-associated Diarrhea In Bone Marrow Transplant Patients 73
Oct 31, 2012: Summit Initiates Phase I Trial Of Oral Antibiotic SMT 19969 For Treatment Of Clostridium Infections 73
Oct 22, 2012: Summit Receives Upto £4.0m Award From Wellcome Trust To Support C. Difficile Antibiotic 74
Oct 15, 2012: Optimer Pharma Announces Presentation Of New Research Findings For Dificid Tablets At IDWeek 2012 75
Oct 02, 2012: Optimer Pharma Introduces Strategic Initiative To Further Facilitate Patient Access To Dificid 75
Sep 27, 2012: AvidBiotics Receives SBIR Grant For Avidocin Antibacterial Proteins Against Clostridium Difficile 76
Sep 25, 2012: Summit Receives Regulatory Approval To Commence Phase I Clinical Trial Of Selective Antibiotic For Treatment Of C. Difficile Infections 76
Sep 06, 2012: Summit Updates Corporate Strategy To Focus On Development Of Clostridium Difficile Program 77
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-315 At ICAAC 2012 78
Aug 06, 2012: Aquapharm Biodiscovery Discovers New Antibiotic Compound 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products Under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2012 9
Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Development by Companies, H2 2012 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Sequella, Inc., H2 2012 19
Merck & Co., Inc., H2 2012 20
Actelion Ltd, H2 2012 21
Cubist Pharmaceuticals, Inc., H2 2012 22
ViroPharma Incorporated, H2 2012 23
Optimer Pharmaceuticals, Inc., H2 2012 24
Paratek Pharmaceuticals, Inc., H2 2012 25
Intercell AG, H2 2012 26
Oragenics, Inc., H2 2012 27
e-Therapeutics plc, H2 2012 28
ActogeniX NV, H2 2012 29
ImmunoBiology Limited, H2 2012 30
Aquapharm Biodiscovery Limited, H2 2012 31
Microbiotix, Inc., H2 2012 32
Sorrento Therapeutics, Inc., H2 2012 33
Assessment by Monotherapy Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics – Drug Profile Updates 62
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics – Discontinued Products 72

List of Figures
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2012 9
Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos